causal

FDA misunderstood psychedelic combination treatment framing

The FDA denied the Lykos/MAPS MDMA-assisted therapy petition partly due to legitimate adverse-event reporting issues and overt bias concerns, but also because the FDA, as a drug-approving body, was confused by the combination treatment framing that emphasized psychotherapy, which falls outside its remit, tripping up the application.

causalpending

Speaker

Robin Carhart-Harris

Evidence Quote

“i think the fda made some errors in terms of their misunderstanding of psychedelic medicine and and therapy ultimately they're a regulatory body that approve drugs drugs as medicines”

Source

478 - The Psychedelic Mind— Making Sense with Sam Harris
Created: 6/14/2026, 2:08:07 AM

Your notes

Loading notes...